Representative Image 
Business

No plans to evaluate divestment options for API biz: Biocon

In a regulatory filing, Bengaluru-based company said it is “neither evaluating any divestment options for its API business nor consulting any bankers for this.” The Active Pharmaceutical Ingredient (API).

DT NEXT Bureau

BENGALURU: Biotechnology major Biocon on Friday said it is not evaluating divestment options for its API business.

In a regulatory filing, Bengaluru-based company said it is “neither evaluating any divestment options for its API business nor consulting any bankers for this.” The Active Pharmaceutical Ingredient (API) business is a strategic business segment of the company and a key growth driver for the company’s small molecules business, a company spokesperson said.

“Biocon continues to strengthen this business and has an ongoing investment of over half a billion dollars in capex and R&D,” the filing said.

The company has a strong pipeline of niche fermentation-based APIs, peptides and high potent API products for the near- and long-term growth of its integrated APIs and generic formulations business, it said. Biocon shares on Friday ended 1.25 per cent down at Rs 251.60 apiece on the BSE.

Deepathoon row: SC permits lamp lighting atop Thiruparankundram hill on Nov 24 as one-time measure

Former DMK Minister Moorthy denies involvement in illegal quarrying

How can Parandur airport project be dropped midway after land acquisition, asks Madras HC

SC dismisses TN's pleas for direction to Karnataka on release of additional water from Cauvery river

Raids on ex-minister Moorthy aimed at diverting attention from drug busts: DMK chief Stalin

SCROLL FOR NEXT